Evidence map›Paper›PMID 35663113›Full record

ArticleJAMIA open2022

Multi-institutional distributed data networks for real-world evidence about medical devices: building unique device identifiers into longitudinal data (BUILD).

Joseph P Drozda, Jove Graham, Joseph B Muhlestein, James E Tcheng, James Roach, Tom Forsyth, Stacey Knight, Andrew McKinnon, Heidi May, Natalia A Wilson and 2 more

Open access · greenAbstract read
In one paragraph

Article in JAMIA open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Joseph P DrozdaMercy, Chesterfield, Missouri, USA.ORCID https://orcid.org/0000-0001-9181-8534
Jove GrahamCenter for Pharmacy Innovation and Outcomes, Geisinger, Danville, Pennsylvania, USA.
Joseph B MuhlesteinIntermountain Medical Center Heart Institute, Salt Lake City, Utah, USA.
James E TchengDepartment of Medicine, Duke University, Durham, North Carolina, USA.
James RoachMercy, Chesterfield, Missouri, USA.
Tom ForsythMercy, Chesterfield, Missouri, USA.
Stacey KnightIntermountain Medical Center Heart Institute, Salt Lake City, Utah, USA.
Andrew McKinnonMercy, Chesterfield, Missouri, USA.
Heidi MayIntermountain Medical Center Heart Institute, Salt Lake City, Utah, USA.
Natalia A WilsonArizona State University, Phoenix, Arizona, USA.
Jesse A BerlinJohnson & Johnson, Titusville, New Jersey, USA.
Edgar P SimardMedtronic, Inc., Minneapolis, Minnesota, USA.
Intermountain Medical Center · USArizona State University · USDuke University · USJohnson & Johnson (United States) · USMedtronic (United States) · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To support development of a robust postmarket device evaluation system using real-world data (RWD) from electronic health records (EHRs) and other sources, employing unique device identifiers (UDIs) to link to device information. Methods: To create consistent device-related EHR RWD across 3 institutions, we established a distributed data network and created UDI-enriched research databases (UDIRs) employing a common data model comprised of 24 tables and 472 fields. To test the system, patients receiving coronary stents between 2010 and 2019 were loaded into each institution's UDIR to support distributed queries without sharing identifiable patient information. The ability of the system to execute queries was tested with 3 quality assurance checks. To demonstrate face validity of the data, a retrospective survival study of patients receiving zotarolimus or everolimus stents from 2012 to 2017 was performed using distributed analysis. Propensity score matching was used to compare risk of 6 cardiovascular outcomes within 12 months postimplantation. Results: The test queries established network functionality. In the analysis, we identified 9141 patients (Mercy = 4905, Geisinger = 4109, Intermountain = 127); mean age 65 ± 12 years, 69% males, 23% zotarolimus. Separate matched analyses at the 3 institutions showed hazard ratio estimates (zotarolimus vs everolimus) of 0.85-1.59 for subsequent percutaneous coronary intervention ( Discussion: The analysis results are consistent with clinical studies comparing these devices. Conclusion: This project shows that multi-institutional data networks can provide clinically relevant real-world evidence via distributed analysis while maintaining data privacy.

Indexed as

drug-eluting stentsmedical device safetyprivacy protectionreal-world evidenceunique device identifier

Identifiers

PMID35663113
PMCPMC9154019
OpenAlexW4282920459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.